CHAMPIONS ONCOLOGY, INC.

CSBR
About the company

Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice through TumorGraft Technology Platform.

Country: United StatesPrice: $4.71Market Cap: $65.5M

Investment snapshot

0%positive consensus
Scored 1d ago

Positive

0

BUY / PASS

Neutral / negative

2 / 14

NEUTRAL / FAIL

Median fair value

—

No comparable estimates

Models with upside

0 / 17

Positive margin of safety

Strongest signal

7 of 12 pass — Graham, Buffett, Lynch +2 more object

Key risk

No clean pass — all 13 investors flag at least one valuation criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILNot rankedFAILFAILFAILFAILFAILFAILFAILNEUTRALFAILFAILFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-07-31 · Balance sheet at 2026-07-31 · Annual history · FY 2025

Latest source filing: 2026-09-11

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-07-27

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-07-31 · TTM ended 2026-07-31 vs 2025-07-31 · TTM ended 2026-07-31

Latest source filing: 2026-09-11

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-07-27

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-07-27

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-07-31 · Balance sheet at 2026-07-31 · Market data at 2026-11-01

Latest source filing: 2026-09-11

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-07-31 · Balance sheet at 2026-07-31

Latest source filing: 2026-09-11

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-07-27

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-07-31 · Balance sheet at 2026-07-31

Latest source filing: 2026-09-11

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-07-27

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-07-31 · Balance sheet at 2026-07-31 · Market data at 2026-11-01

Latest source filing: 2026-09-11

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-07-31

Latest source filing: 2026-09-11

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-07-27

Score computed: 2026-11-14

TTM ended 2026-07-31 · Balance sheet at 2026-07-31 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-09-11

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-07-31

Latest source filing: 2026-09-11

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-07-31

Latest source filing: 2026-09-11

Score computed: 2026-11-14

TTM ended 2026-07-31 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-09-11

Score computed: 2026-11-14

Where It Passes

  • Debt & Leverage58% pass✓ 10✗ 5▾

    7 of 12 pass — Graham, Buffett, Lynch +2 more object

    LT Debt vs Net Current Assets
    ✗GrahamLT Debt <= Net Current Assets
    Debt/Equity & Interest CoverageD/E: 0.02, IC: N/A
    ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
    Total Debt / Equity0.02
    ✓Lynch< 0.33
    Cash - Long-term Debt
    ✗LynchPositive preferred
    LT Debt / Total Assets Change0.00% -> 0.00%
    ✓PiotroskiDecreased YoY
    Current Assets / Current Liabilities1.03
    ✗Dreman> 1.5✗SchlossCurrent ratio >= 1.50x (app cutoff)
    Total Debt / Shareholders' Equity0.02
    ✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x
    Debt Levels0.02
    ✓MungerDebt/Equity < 0.5✓AkreDebt/Equity < 0.3
    Interest Coverage & Debt/EBITDAIC=N/A (no interest expense), D/EBITDA=0.3x
    ✓MarksInterest Coverage > 3x; Debt/EBITDA < 4x
    Total Debt / Shareholders Equity0.02
    ✓Ackman<= 1.0
    Negative debt-to-equity (higher means less debt)-0.0170; #718/4210 (top 17.1%)
    ✓AsnessTop 30% of eligible cross-section

Where It Falls Short

  • Valuation0% pass✓ 1✗ 27▾

    No clean pass — all 13 investors flag at least one valuation criterion

    Price / 3-yr avg EPS
    ✗Graham<= 15x
    Price-to-Book Ratio16.6x
    ✗Graham<= 1.5x
    P/E x P/B
    ✗Graham<= 22.5
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    EBIT / Enterprise Value-1.9%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=-1.9%, ROC=N/A (invested capital <= 0)
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Price / EPS
    ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
    Price / (CFO / Shares)N/A (negative CFPS)
    ✗Dreman< 8x
    Price / Book Value per Share16.6x
    ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
    Valuation ReasonablenessOE Yield=-0.5%
    ✗MungerP/E < 25 or Owner Earnings Yield > 5%
    P/E or FCF YieldFCF Yield=-7.7%
    ✗PabraiP/E < 15 or FCF Yield > 10%
    P/B or P/E vs. Historical AverageP/B=16.6x
    ✗MarksP/E < 15 or P/B < 2.0
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Price / FCF per ShareN/A (negative FCF)
    ✗Ackman<= 25
    Price vs. Trailing Low100% of trailing low ($4.71)
    ✓Templeton<= 120% of trailing low (certified split-adjusted live window)
    Net income / market capitalization-1.69%; #3512/6340 (top 55.4%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Positive book equity / market capitalization+0.0594; #4957/6449 (top 76.9%)
    ✗AsnessTop 30% of eligible cross-section
    Price / Diluted EPS
    ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
    (EPS CAGR % + Dividend Yield %) / P/E
    ✗Neff> 0.7 (Neff's published traditional edge)
    Price / Tangible Book Value per Share18.16x
    ✗SchlossP/TBV <= 1.00x (app cutoff)
    Book Value per Share Change-48.8%
    ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
    Revenue / market capitalization+0.9263; #1848/5247 (top 35.2%)
    ✗OshaughnessyTop 10% of eligible cross-section
    (Operating cash flow - capex) / market capitalization-9.37%; #3207/4519 (top 71.0%)
    ✗OshaughnessyTop 10% of eligible cross-section
    Trailing six-month price return through the evaluation date-18.09%; #3873/6202 (top 62.4%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Cash Flow0% pass✗ 12▾

    All 10 investors flag CSBR's cash flow

    Free Cash Flow Proxy$-0.3M
    ✗BuffettPositive and growing
    FCF Positive and Growing$-6.1M
    ✗LynchPositive and growing
    Operating Cash Flow$-4.5M
    ✗PiotroskiCFO > 0
    (CFO / Total Assets) vs ROACFO/Assets=-16.57%, ROA=-4.35%
    ✗PiotroskiCFO/Assets > ROA
    Price / (CFO / Shares)N/A (negative CFPS)
    ✗Dreman< 8x
    P/E or FCF YieldFCF Yield=-7.7%
    ✗PabraiP/E < 15 or FCF Yield > 10%
    FCF Positive5/16 years FCF positive
    ✗MarksPositive FCF in majority of recent years
    (OCF - CapEx) / Market Cap-9.4%
    ✗Ackman>= 4%
    Price / FCF per ShareN/A (negative FCF)
    ✗Ackman<= 25
    Positive Operating Cash Flow frequency5/16 years positive
    ✗SleepPositive OCF in >= 70% of available years
    Operating Cash Flow - Capital Expenditures$-6.1M
    ✗Neff> $0 (app proxy for a strong fundamental case)
    (Operating cash flow - capex) / market capitalization-9.37%; #3207/4519 (top 71.0%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Verdicts0% pass✗ 14▾

    Split decision: 14 FAIL · 2 NEUTRAL

    Overall verdict
    ✗GrahamFAIL (0/9)✗BuffettFAIL (2/9)✗LynchFAIL (2/7)•GreenblattNot ranked✗PiotroskiFAIL (F-Score 3)✗DremanFAIL (2/11)✗MungerFAIL (1/4)✗PabraiFAIL (0/3)✗AkreFAIL (2/6)✗MarksFAIL (1/5)✗AckmanFAIL (2/9)•TempletonNEUTRAL (5/8)✗SleepFAIL (2/6)✗AsnessFAIL (Rank #1747/2370 (Top 73.7%))✗NeffFAIL (1/6)✗SchlossFAIL (1/7)•OshaughnessyNEUTRAL (Not ranked)
  • Profitability6% pass✓ 3✗ 32▾

    15 of 16 flag CSBR's profitability — Graham, Buffett, Lynch +12 more

    Positive EPS (10 years)4/19 years positive
    ✗GrahamPositive EPS every year for 10 years
    EPS Growth (3-yr avg, 10-yr window)
    ✗Graham>= 33% growth
    Net Income Positive (10+ years)4/19 years positive
    ✗BuffettPositive every year for 10+ years
    ROE (up to 5-year arithmetic mean)-1.9%
    ✗Buffett> 15% arithmetic mean (app rule)
    Operating Margin (10-yr trend)-1.9% (latest)
    ✗BuffettStable or rising over 10 years
    Free Cash Flow Proxy$-0.3M
    ✗BuffettPositive and growing
    Earnings Variance (10-yr CoV)
    ✗BuffettCoV < 0.3
    Retained Earnings Effectiveness
    ✗Buffett$1 retained -> > $1 market value created
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    ROE-28.4%
    ✗Lynch> 15%
    EBIT / Enterprise Value-1.9%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=-1.9%, ROC=N/A (invested capital <= 0)
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Net Income / Total Assets-4.35%
    ✗PiotroskiROA > 0
    ROA Change YoY14.53% -> -4.35% (delta: -18.89%)
    ✗PiotroskiCurrent ROA > Prior ROA
    (CFO / Total Assets) vs ROACFO/Assets=-16.57%, ROA=-4.35%
    ✗PiotroskiCFO/Assets > ROA
    Gross Margin Change YoY50.1% -> 48.0%
    ✗PiotroskiImproved YoY
    Pre-Tax Income / Revenue-1.5%
    ✗Dreman>= 8%
    Net Income / Shareholders' Equity-28.4%
    ✗Dreman> 12%
    Margin of SafetyP/B=16.6x
    ✗PabraiP/B < 1.5 or P/E < 15
    Return on Equity-6.8% (3-yr avg)
    ✗AkreROE > 20% (3-year avg)
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Positive Net Income Frequency4/16 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    Operating Income / Revenue-1.7%
    ✗Ackman>= 15%
    Net Income / Shareholders Equity-28.4%
    ✗Ackman>= 15%
    5-Year EPS CAGR101.5% CAGR over 4 years
    ✓Templeton> 0% (5-year EPS CAGR)
    Operating Margin Trend-14.7% (2023) -> -1.9% (2025)
    ✓TempletonNon-negative operating-margin trend over 3 years
    Revenue growth vs. gross and operating margin trendgross margin 41.4% -> 48.0%, operating margin -14.7% -> -1.9%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    Net income / market capitalization-1.69%; #3512/6340 (top 55.4%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Gross profit / total assets+105.69%; #135/3702 (top 3.6%)
    ✓AsnessTop 30% of eligible cross-section
    Net income / positive book equity-28.36%; #3877/5226 (top 74.2%)
    ✗AsnessTop 30% of eligible cross-section
    Negative 5-year standard deviation of ROA-0.1449; #3909/5884 (top 66.4%)
    ✗AsnessTop 30% of eligible cross-section
    3-5 Year Diluted EPS CAGR101.5% over 4 years
    ✗Neff7%-20% annualized
    Positive Diluted-EPS Years4/10 years positive
    ✗Schloss>= 70% positive over 5-10 observed years (app rule)
  • Growth13% pass✓ 4✗ 9▾

    7 of 8 flag CSBR's growth — Graham, Lynch, Dreman +4 more

    EPS Growth (3-yr avg, 10-yr window)
    ✗Graham>= 33% growth
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    Inventory Growth vs Revenue GrowthN/A (no inventory)
    ✓LynchInventory growth < Revenue growth
    EPS Growth Direction
    ✗DremanPositive over recent years
    EPS CAGR79.1% CAGR over 6 years
    ✓Dreman> 5% annualized
    Positive Net Income Frequency4/16 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    3yr Median Revenue Growth4.4%
    ✗Ackman>= 5%
    Positive EPS Growth Frequency2/5 years with positive EPS growth
    ✗AckmanPositive EPS growth in >= 3 of last 5 years
    5-Year EPS CAGR101.5% CAGR over 4 years
    ✓Templeton> 0% (5-year EPS CAGR)
    Revenue growth vs. gross and operating margin trendgross margin 41.4% -> 48.0%, operating margin -14.7% -> -1.9%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    5-year Revenue CAGR7.7%
    ✓SleepCAGR > 7%
    3-5 Year Diluted EPS CAGR101.5% over 4 years
    ✗Neff7%-20% annualized
  • Efficiency25% pass✓ 4✗ 7▾

    6 of 8 flag CSBR's efficiency — Graham, Greenblatt, Dreman +3 more

    Current Ratio1.03
    ✗Graham>= 2.0
    ROIC (3-5 yr avg)154.2%
    ✓Buffett> 10%
    ROIC - WACC+144.2%
    ✓BuffettPositive (WACC = 10%)
    EBIT / (NWC + Net Fixed Assets)N/A (invested capital <= 0)
    ✗Greenblatt> 25%
    Current Ratio Change YoY0.94 -> 0.96
    ✓PiotroskiIncreased YoY
    Revenue / Total Assets Change YoY1.76x -> 2.20x
    ✓PiotroskiImproved YoY
    Current Assets / Current Liabilities1.03
    ✗Dreman> 1.5
    Return on Invested Capital-20.4%
    ✗Munger> 15%
    ROIC (high and growing)FY2023: ROIC=unavailable; FY2024: ROIC=90.1%; FY2025: ROIC=-22.4%
    ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
    Reinvestment Rate x ROICN/A (non-positive net income)
    ✗AkreReinvestment Rate * ROIC > 10%
    ROIC (5-year)1/4 years above 12% (latest -22.4%)
    ✗SleepROIC > 12% in a majority of years

Business & financials

Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

Company Profile

Industry: Pharmaceutical Products
SIC Sector: Chemicals & Pharmaceuticals
Size: Micro Cap($65.5M)
Revenue: $59.4M+4.4% YoY
Net Income: $1.2M-125.0% YoY

Financial Snapshot

Operating Margin-1.9%
Return on Equity-29.8%
Debt / Equity0.02
Current Ratio0.96
EPS (Diluted)$-0.08
Shares Retired−0.8% / −2.5% 2y

Similar Companies

MRKMerck & Co., Inc.
$364.3B
ABTABBOTT LABORATORIES
$188.0B
BMYBRISTOL MYERS SQUIBB CO
$129.7B
TECHBIO-TECHNE Corp
$11.4B

Shareholder Return

Fiscal 2025

Issued 0.8% of shares last year, 2.5% issued over two.

Buybacks
—
Dividends
—

Company Financials

Latest TTM and quarters alongside annual years

TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

MetricTTM · 2026-07-31

2025-08-01 – 2026-07-31

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, capex, revenue, net income, operating income, ebit, pre tax income, depreciation amortization.

Q1 FY 2027

2026-05-01 – 2026-07-31

Sources
FY 2025
Sources
  • 10-K · 2026-07-27
FY 2024
Sources
  • 10-K · 2025-07-23
FY 2023
Sources
  • 10-K · 2024-07-19
FY 2022
Sources
  • 10-K · 2023-07-24
FY 2021
Sources
  • 10-K · 2022-07-22
Market Cap$65.5Mcurrent--$101.6Mest.$151.4Mest.$78.8Mest.$55.3Mest.$108.4Mest.
Revenue$60.7M↑7%$15.2M↑9%$59.4M↑4%$56.9M↑14%$50.2M↓7%$53.9M↑10%$49.1M
Operating Income-$1.0M↓138%-$409.0K↑22%-$1.1M↓125%$4.6M↑162%-$7.4M↓40%-$5.3M↓966%$607.0K
Net Income-$1.1M↓137%-$426.0K↑2%-$1.2M↓125%$4.7M↑165%-$7.3M↓36%-$5.3M↓1074%$548.0K
EPS (Diluted)----$-0.08↓124%$0.33↑161%$-0.54↓38%$-0.39↓1075%$0.04
Gross Margin——48.0%↓4%50.1%↑21%41.4%↓8%45.2%↓13%51.9%
Operating Margin-1.7%↓136%-2.7%↑29%-1.9%↓124%8.0%↑155%-14.7%↓50%-9.8%↓889%1.2%
ROE-28.4%↓134%—-29.8%↓124%124.6%↓67%382.3%↑432%-115.1%↓2010%6.0%
Total Debt$66.0K↓64%$66.0K↓64%$86.0K↓61%$220.0K↓41%$371.0K↑156%$145.0K↑101%$72.0K
Shareholders' Equity$3.9M↑11%$3.9M↑11%$3.9M↑4%$3.8M↑298%-$1.9M↓141%$4.6M↓49%$9.1M
Current Ratio1.03↑11%1.03↑11%0.96↑3%0.94↑48%0.63↓29%0.90↓20%1.13
Debt / Equity0.02↓67%0.02↓67%0.02↓63%0.06↑130%-0.19↓723%0.03↑295%0.01
Operating Cash Flow-$5.6M↓172%-$492.0K↓182%-$4.5M↓161%$7.4M↑220%-$6.1M↓255%$4.0M↓39%$6.5M
Free Cash Flow-$6.1M↓185%-$547.0K↓199%-$5.0M↓172%$7.0M↑200%-$7.0M↓734%$1.1M↓73%$4.1M

Score history

Historical Score Timeline

Industry peers

Industry Peers

Similar companies in Pharmaceutical Products

CSBR vs Peers — Financial Grading

Revenue$59.4MBottom 25%
Net Income$1.2MMedian
ROE-29.8%Bottom 25%
D/E0.02Top 25%
Op. Margin-1.9%Median
Curr. Ratio0.96Bottom 25%
CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
Merck & Co., Inc.MRK$364.3B$147.76$65.0B$18.3B34.7%0.94—1.542/95/94/70/3F-Score 41/11
ABBOTT LABORATORIESABT$188.0B$108.52$44.3B$6.5B12.5%0.2518.2%1.583/94/92/71/3F-Score 53/11
BRISTOL MYERS SQUIBB COBMY$129.7B$63.43$48.2B$7.1B38.2%2.4419.4%1.262/91/93/71/3F-Score 85/11
BIO-TECHNE CorpTECH$11.4B$72.80$1.2B$73.4M3.8%—8.4%3.464/93/93/70/3F-Score 54/11
REPLIGEN CORPRGEN$10.7B$167.79$738.3M$48.9M2.3%0.267.5%8.373/92/93/70/3F-Score 75/11
IONIS PHARMACEUTICALS INCIONS$4.8B$29.06$943.7M$381.4M-78.0%3.60-40.4%3.833/91/91/70/3F-Score 43/11
NEOGEN CORPNEOG$2.5B$11.23$870.4M$7.9M-0.4%0.76-2.5%3.823/91/92/70/3F-Score 64/11
Pharvaris N.V.PHVS$2.4B$33.36—$206.4M-64.8%0.00——0/90/92/70/3F-Score 22/11